The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CX-01, an inhibitor of CXCL12/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS.
 
Eric Huselton
No Relationships to Disclose
 
Amanda F. Cashen
Consulting or Advisory Role - Epizyme; Kite, a Gilead company; Pharmacyclics
Speakers' Bureau - Celgene; Gilead Sciences; Novartis; Seagen
Research Funding - Spectrum Pharmaceuticals
 
Meagan Jacoby
No Relationships to Disclose
 
Iskra Pusic
No Relationships to Disclose
 
Rizwan Romee
No Relationships to Disclose
 
Geoffrey L. Uy
Consulting or Advisory Role - Curis; Glycomimetics; Jazz Pharmaceuticals; Novartis; Novo Nordisk; Pfizer
Travel, Accommodations, Expenses - Novartis
 
John F. DiPersio
Honoraria - Incyte; Seagen
Consulting or Advisory Role - Genentech; Macrogenics
Research Funding - Daiichi Sankyo (Inst)
 
Peter Westervelt
Research Funding - Cantex Pharmaceuticals (Inst)